Bayesian procedures for phase I/II clinical trials investigating the safety and efficacy of drug combinations

Statistics in Medicine

Volumn 30, Issue 16, 2011, Pages 1952-1970

  Whitehead, John ^a   Thygesen, Helene ^a   Whitehead, Anne ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Combination therapies; Decision procedure; Dose finding; Phase I II clinical trials

Indexed keywords

GEMCITABINE; MK 0752;

ARTICLE; BAYES THEOREM; BIVARIATE ANALYSIS; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROBABILITY; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIMULATION; STATISTICAL MODEL; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BAYES THEOREM; BIOSTATISTICS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79959214063     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4267     Document Type: Article

References (16)

1. Whitehead J, Thygesen H, Whitehead A. A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity. Statistics in Medicine 2010; 29:1808-1824.
2. Tamhane AC, Logan BR. Multiple test procedures for identifying the minimum effective and maximum safe doses of a drug. Journal of the American Statistical Association 2002; 97:293-301.
3. Bretz F, Hothorn LA, Hsu JC. Identifying effective and/or safe doses by stepwise confidence intervals for ratios. Statistics in Medicine 2003; 22:847-858.
4. Loke Y-C, Tan S-B, Cai YY, Machin D. A Bayesian dose finding design for dual endpoint phase I trials. Statistics in Medicine 2006; 25:3-22.
5. Dragalin V, Fedorov VV, Wu Y. Two-stage design for dose-finding that accounts for both efficacy and safety. Statistics in Medicine 2008; 27:5156-5176.
6. Messer K, Natarajan L, Ball ED, Lane TA. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials. Statistics in Medicine 2010; 29:712-720.
7. Hung HMJ, Chi GYH, Lipicky RJ. On some statistical methods for analysis of combination drug studies. Communications in Statistics A 1994; 23:361-376.
8. Hung HMJ. Evaluation of a combination drug with multiple doses in unbalanced factorial design clinical trials. Statistics in Medicine 2000; 19:2079-2087.
9. Hellmich M, Lehmacher W. Closure procedures for monotone bi-factorial dose-response designs. Biometrics 2005; 61:269-276.
10. Thall PF, Millikan RE, Mueller P, Lee S-J. Dose-finding with two agents in Phase I oncology trials. Biometrics 2003; 59:487-496.
11. Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics 2005; 61:217-222.
12. Huang X, Biswas S, Oki Y, Issa J-P, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007; 63:429-436.
13. Mandrekar SJ, Qin R, Sargent DJ. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Statistics in Medicine 2010; 29:1077-1083.
14. Robertson T, Wright FT, Dykstra RL. Order Restricted Statistical Inference. Wiley: New York, 1988.
15. Whitehead J, Williamson D. Bayesian decision procedures based on logistic regression models for dose-finding studies. Journal of Biopharmaceutical Statistics 1998; 8:445-467.
16. Ottosson RO, Engstrom PE, Sjostrom D, Behrens CF, Karlsson A, Knoos T, Ceberg C. The feasibility of using Pareto fronts for comparison of treatment planning systems and delivery techniques. Acta Oncologica 2009; 48:233-237.